Tissue Engineering Market

The global tissue engineering market was valued at $2,374 million in 2019, and is projected to reach $6,815 million by 2027, registering a CAGR of 14.2% from 2020 to 2027.

Tissue engineering is an interdisciplinary field that applies principles of engineering and life sciences toward development of biological substitutes that restore, maintain, or improve tissue function. To do this process, cells and biomolecules are combined with scaffolds. Scaffold is an artificial or natural structure that mimics real organs. 

Increase in prevalence of chronic diseases & trauma emergencies, rise in awareness related to tissue engineering, technological advancements in 3D bio-printing ,and potential pipeline products drive the market growth. Furthermore, growth in number of R&D activities with rise in awareness of tissue engineering in emerging economies are expected to support the market growth. In addition, increase in focus of key players on tissue engineering based therapies are expected to enhance the tissue engineering market growth during the forecast period. However, stringent government regulations and high cost of treatment are estimated to hamper growth of the market.

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. Healthcare industries have been largely impacted by COVID-19 pandemic. After the COVID?19 pandemic, clinical research in tissue engineering are made unavailable and non?COVID?19 clinical trials are significantly reduced. Meanwhile, many of pharmaceutical and biotech companies have shifted their focus on development of drugs and vaccines for treatment of COVID?19. In addition, significant reduction in cell and tissue donation programs negatively impact growth of the tissue engineering market. Thus, delay & disruptions in clinical research and cancelations or delays in tissue replacement & reconstructive surgeries impend the tissue engineering market growth. 

Tissue Engineering Market Segmentation  

The global tissue engineering market is segmented into type, application, and region. On the basis of type, the market is categorized into synthetic scaffold material, biologically derived scaffold material, and others. The synthetic scaffold material segment is further categorized into synthetic polymer and others. The biologically derived scaffold material segment is sub segmented into collagen and others. On the basis of application, the market is segregated into orthopedics & musculoskeletal, neurology, cardiovascular, skin & integumentary, dental and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. 

Segment review 

On the basis of type, the market is categorized into synthetic scaffold material, biologically derived scaffold material, and others. The synthetic scaffold materials segment is expected to grow significantly, owing to its efficiency over other naturally derived materials. Synthetic materials are preferred over other materials as they provide a better outcome.  Presently, the biologically derived materials segment is major revenue contributor in the tissue engineering market, owing to its properties such as biocompatibility, non-toxicity, biodegradability, good cell recognition properties, and easy functionalization.

On the basis of application, the market is categorized into orthopedics & musculoskeletal, neurology, cardiovascular, skin & integumentary, dental, and others. The tissue engineering market for orthopedics & musculoskeletal application is expected to witness significant growth, owing to rise in adoption of tissue engineered products for orthopedics & musculoskeletal applications, rise in commercialization for bone and cartilage repair tissue engineered products, wide availability of products, and rise in incidences of musculoskeletal disorders with increase in awareness of tissue engineered products. It is estimated the cardiovascular segment would show the highest market growth, owing to rise in incidences of cardiovascular diseases and surge in R&D activities to develop tissue engineered products for cardiology. 

Snapshot of Asia-Pacific tissue engineering market  

Asia-Pacific presents lucrative opportunities for key players operating in the tissue engineering market, owing to its growth in awareness regarding tissue engineered products, rise in demand for advanced healthcare services in emerging economies, developing R&D sector, and rise in presence of key players in the region. Furthermore, developing healthcare infrastructure and increase in focus on regenerative medicine has led to rapid developments in the market. 

The key players profiled in this report include  AbbVie Inc. (Allergen Plc.), B. Braun Melsungen AG, Becton, Dickinson and Company (C. R. BARD, INC.), Integra LifeSciences, Organogenesis Holdings, Sid Martin Biotech (Axogen), Smith & Nephew Plc. (Osiris Therapeutics), TissueTech Inc., Vericel Corporation, and Zimmer Biomet Holdings, Inc.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the tissue engineering market size along with current trends and future estimations to elucidate the imminent investment pockets.
• It offers tissue engineering market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
• A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global tissue engineering market growth.

 Tissue Engineering Market Report Highlights